Plogosertib is under clinical development by Cyclacel Pharmaceuticals and currently in Phase II for Metastatic Hepatocellular Carcinoma (HCC). According to GlobalData, Phase II drugs for Metastatic Hepatocellular Carcinoma (HCC) have a 23% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Plogosertib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Plogosertib is under development for the treatment of solid tumors including triple negative breast cancer, esophageal cancer, colorectal cancer, myelodysplastic syndrome and blood cancer including chronic lymphoblastic leukemia (CLL), relapsed/refractory acute myeloblastic leukemia, relapsed/refractory leukemias, small-cell lung cancer, non-small cell lung cancer, bladder cancer, hepatocellular carcinoma, metastatic biliary tract cancer, diffuse large b-cell lymphoma, cutaneous t-cell lymphoma, peripheral t-cell lymphomas, ovarian cancer, prostate cancer, cholangiocarcinoma, gall bladder cancer and pancreatic cancer. It is a small molecule administered through oral and intravenous route. It acts by targeting polo-like kinase 1 (Plk1). Polo-like kinases play critical roles during multiple stages of cell cycle progression. Polo-like kinase (PLK) inhibitors targets the mitotic phase of the cell cycle. The drug candidate is based on genomic technology.
Cyclacel Pharmaceuticals overview
Cyclacel Pharmaceuticals (Cyclacel) is a biopharmaceutical company that develops oral therapies. The company develops small molecule drugs that target various phases of cell cycle control for the treatment of cancer and other serious diseases. Its products include sapacitabine, seliciclib, PLK inhibitor and CDK inhibitor. Cyclacel’s sapacitabine is the drug candidate used to treat the patients with acute myeloid leukemia. Cyclacel seliciclib is an orally available, cyclin dependent kinase inhibitor. It offers products for the treatment of anti-infective, autoimmune, cardiovascular, ophthalmic and other non-oncology indications. The company operates in the US and the UK. Cyclacel is headquartered in Berkeley Heights, New Jersey, the US.
For a complete picture of Plogosertib’s drug-specific PTSR and LoA scores, buy the report here.